Drugs / MK-1167
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07334860 | Feb → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07266818 | Dec 2025 → Apr 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06285240 | Mar → Sep 2024 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06703463 | Oct 2023 → Feb 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06625840 | Sep 2023 → May 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06721156 | Dec 2024 → Jun 2026 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-01 | Merck Sharp & Dohme LLC | MSD Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 msd.com ↗ |
| 2025-12-01 | Merck Sharp & Dohme LLC | Merck Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 merck.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07334860 ↗ |
| Route | Oral | “6mg MK-1167 oral loading doses” NCT06285240 ↗ |